FMI expects global Antibiotics Active Pharmaceutical Ingredient (API) Market demand to grow at 3.1% CAGR through 2030. Any type of surgery or long-term illness makes the patient more vulnerable to bacterial infection. The market for antibiotics API is anticipated to be driven by the rising prevalence of infections such tuberculosis, pneumonia, blood poisoning, gonorrhoea, and foodborne illnesses.
The World Health Organization (WHO) states that bacterial pneumonia can be treated with antibiotics. Around 15% of child mortality in 2017 were caused by pneumonia. The prevalence of pneumonia is over 1,400 cases per 100,000 children worldwide, with South Asia and West and Central Africa having the highest occurrences (2,500 cases per 100,000 children each), according to UNICEF data from 2018. (1,620 cases per 100,000 children)
Request a report sample to gain comprehensive insights @
https://www.futuremarketinsights.com/reports/sample/rep-gb-13025
The COVID-19 pandemic is anticipated to have a detrimental effect on the market for antibiotic APIs. Several of the biggest pharmaceutical companies, research universities, and biotech companies have been chosen to address the issue. They are now focusing on creating coronavirus vaccines rather than other drugs as a result. Hospital beds are scarce, and several APIs are in short supply.
Due to the rising demand and widespread use of penicillin as a first-line antibiotic therapy to treat various bacterial infections, the penicillin antibiotics segment dominated the antibiotics API market in 2021 with a market share of 51.1%. It is anticipated that pharmaceutical corporations will dominate the end user market. Through the projected period, they are anticipated to hold more than 77% of the market and continue to dominate.
Key Takeaways from Antibiotics API Market Study
- The global antibiotics API market is estimated to be US$ 8.01 Bn in 2020, with the market expected to exhibit a CAGR of 3.1% during the forecast period (2020-2030)
- The U.S. holds over 92.1% share of the North America market, but Canada is projected to expand faster CAGR
- The U.K. market will showcase steady y-o-y growth at 2.1% in 2021
- The demand from Germany and France will rise at a positive rate through the forecast period
- Within East Asia China will emerge as a key market, while Japan and South Korea will continue exhibiting steady demand
For any Queries Related with the Report, Ask an Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-13025
“Increasing prevalence of bacterial diseases, extreme use of antibiotics and rising investment in R&D are expected to boost the growth of the antibiotics API market.” says the FMI Analyst
Rising investment in R&D sector in order to develop advanced molecules is the major factor expected to boost the antibiotic API market growth.
For instance, Sandoz, the Novartis biosimilars and generics division, undergoes a joint investment, with the Austrian federal government, to enhance the long-term future of integrated antibiotics manufacturing in Europe.
Key players in the Antibiotics API are Entering into Strategic Alliance
The top players are focusing on increasing acquisitions at regional levels. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires to possess well-established products and solutions that expects to account good revenue source for the acquirer. This also enables the company to enter new emerging markets as well as enhance the existing markets.
Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-13025
For instance, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, for elevating the manufacturing capacity of the active pharmaceutical ingredients in the region of U.S. The collaboration enabled Meitheal Pharmaceuticals to invest into the Nanjing Dorra Pharmaceutical Technology.
Who is Winning?
The global antibiotics API market is set to expand its scope in the forecast period, as a result of rising prevalence of various bacterial diseases, and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are more focused towards outsourcing of antibiotics API manufacturing due to the involvement of high capital investment in the establishment of Antibiotics API manufacturing units.
The key market players covered by FMI include Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.
Use promo code >> FMITODAY to get flat 20% discount
Antibiotics API Market by API Type:
API Type
- Penicillin Antibiotics
- Ampicillin
- Amoxicillin
- Dicloxacillin
- Penicillin G Sodium
- Benzathine
- Procaine
- Cephalosporins
- Cefotaxime
- Ceftriaxone
- Cefuroxime
- Cefalotin
- Carbapenem Antibiotics
- Meropenem
- Imipenem
- Ertapenem
End User
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Contract Development & Manufacturing Organizations (CDMOs)
Top Related Reports Healthcare Market Insights:
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
